From August 12, 2026 to September 1, 2026, the company acquired 532,400 ordinary shares as treasury stock through market purchases for a total of 1,999,802,000 yen. The upper limit was 700,000 shares (3.13% of issued shares) and up to 2,000,000,000 yen; the planned acquisition period was August 12, 2026 to September 7, 2026 (resolutions date), but the actual acquisition ended on September 1.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2664-20260902-01.pdf","jir_short_summary":"From August 12, 2026 to September 1, 2026, the company acquired 532,400 ordinary shares as treasury stock through market purchases for a total of 1,999,802,000 yen. The upper limit was 700,000 shares (3.13% of issued shares) and up to 2,000,000,000 yen; the planned acquisition period was August 12, 2026 to September 7, 2026 (resolutions date), but the actual acquisition ended on September 1.","jir_summary":"### Summary of the acquisition\nToday, we announce the execution of treasury stock acquisition under Article 165, Paragraph 2 of the Companies Act. The target is the company's ordinary shares, with the acquisition period from August 12, 2026 to September 1, 2026, total shares 532,400, and total amount 1,999,802,000 yen. The transactions were conducted via market purchases on the Tokyo Stock Exchange.\n\n### Outlook and notes\nAt the Board of Directors meeting held on August 3, the upper limit was set at 700,000 shares (3.13% of issued shares) and up to 2,000,000,000 yen, with a period from August 12 to September 7. This acquisition is a realized portion or entirety of that plan, ending within the established upper limits for both amount and shares. We will monitor market trends and potential dilution effects if further disclosures are made.","jir_financial_highlights":"Total number of treasury shares acquired: 532,400 shares (Unknown)\nTotal acquisition value: 1,999,802,000 yen (Unknown)\nAcquisition period: August 12, 2026 to September 1, 2026 (Unknown)","jir_category":"","jir_hashtags":"#KawachiPharmaceuticals, #ShareBuyback","jir_key_figures":"532,400 \u682a: \u53d6\u5f97\u682a\u5f0f\u6570\n1,999,802,000 \u5186: \u53d6\u5f97\u7dcf\u984d\n\u4e0a\u9650700,000 \u682a\uff083.13%\uff09\/ 2,000,000,000 \u5186: \u4e0a\u9650\u60c5\u5831","jir_meta_title":"Kawachi Pharmaceuticals \u2013 Disclosure of treasury stock acquisition results | 532,400 shares, approx. 19.998 billion yen; acquisition concluded","jir_meta_description":"Kawachi Pharmaceuticals discloses treasury stock acquisition results. 532,400 shares acquired, total approx. 19.998 billion yen, acquisition period 2026\/8\/12-9\/1, upper limit 700,000 shares and 2,000 million yen. Focus on dilution control developments.","jir_og_title":"Kawachi Pharmaceuticals \u2013 Disclosure of treasury stock acquisition results | 532,400 shares, approx. 19.998 billion yen","jir_og_description":"Kawachi Pharmaceuticals conducted treasury stock acquisition, acquiring 532,400 shares for a total of 19.998 billion yen, with a period of 2026\/8\/12-9\/1 and upper limits of 700,000 shares and 2,000 million yen. It has concluded.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-109992","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n